



Agrochemical Residue Field Trials (RFT) Sub-Group Annual Report

CORESTA Congress/Online

October 2020



❖ 1st Generation Candidate (23CPAs)

- Status / as of 2019
- Trial Status and Plan / as of January 2020
- Trial Status and Plan update / **as of September 2020.**

❖ 2nd Generation Candidate (9CPAs)

- Trial Plan update / as of January 2020
- Trial Status update / **as of September 2020**



1st Generation Candidates (23 CPAs)



Status / as of 2019

#	CPA name	Status	#	CPA name	Status	#	CPA name	Status
1	Azoxystrobin	GRL	9	Ethion	Ongoing	17	Spirotetramat	Ongoing
2	Difenoconazole	GRL	10	Triazophos	Ongoing	18	Bitertanol	Delisted
3	Indoxacarb	GRL	11	Fenamidone	GRL	19	Iprobenfos	Delisted
4	Propamocarb	GRL	12	Flubendiamide	GRL	20	Thiacloprid	Ongoing
5	Tebuconazole	GRL	13	Clothianidin	Ongoing	21	Chlorfenapyr	Delisted
6	Chlorantraniliprole	GRL	14	Dicofol	Delisted	22	Prothiofos	Delisted
7	Triflumuron	GRL	15	Teflubenzuron	GRL	23	Quinalphos	Delisted
8	Triadimefon/nol	Ongoing	16	Iprovalicarb	Ongoing			



Trial Status and Plan / as of January 2020

#	CPA name	No. of Ctry	'13	'14	'15	'16	'17	'18	'19	'20	'21	'22	Total	Remark
8	Triadimefon/nol	1	3	2	2	2	1						10	
9	Ethion	1					2	2	2				6	
10	Triazophos	1					2	2	2				6	
13	Clothianidin	2	3	2	2	4	3	2					16	
16	Iprovalicarb	1				1	1	1					3	
17	Spirotetramat	3				2	2	2	1	3	3	2	15	
20	Thiacloprid	3	2	2	2					2	2	2	12	

Completed

On going / Plan



Trial Status and Plan update

/ as of September

❖ 5 CPAs

- Trials for Triadimefon/nol, Ethion, Triazophos, Clothianidin and Iprovalicarb have been finished.
- The data obtained from the trials will be used to discuss future technical GRLs.

❖ 2 CPAs

- Additional trials for Spirotetramat and Thiacloprid were planned in Philippines and India
- 2020 trials for Spirotetramat was finished in Philippines.
- Other 2020 trials in India are on going (close to completion).
- All trials for Spirotetramat and Thiacloprid will be finished in 2022.



Trial Status and Plan update

/ as of September

#	CPA name	No. of Ctry	'13 -'17	'18	'19	'20	'21	'22	Total	Remark	
8	Triadimefon/nol	1	10						10	Finished	
9	Ethion	1	2	2	2				6	Finished	
10	Triazophos	1	2	2	2				6	Finished	
13	Clothianidin	2	14	2					16	Finished	
16	Iprovalicarb	1	2	1					3	Finished	
17	Spirotetramat	3	4	2	1	1	2	3	2	15	Fin. 2022
20	Thiacloprid	3	6			2	2	2		12	Fin. 2022

Completed

On going / Plan



2nd Generation Candidates (9 CPAs)

❖ AR: Executor for S-metolachlor

- In Argentina, 4 executors participated in the trial for S-metolachlor from 2019/2020 crop.
 - AOI, CTJ (Jujuy) and AOI, COPROTAB (Salta)
- Total trial no. of S-metolachlor became 39 in 5 countries by 7 executors.

❖ IN: ITC participation

- ITC finished the trials for 8 CPAs from 2017-2019.
 - Azoxystrobin, Chlorantraniliprole, Difenoconazole, Fenamidone, Flubendiamide, Tebuconazole, Ethion, Triazophos
- ITC agreed to participate in the future trials for 4 CPAs from 2020-2022.
 - Trifloxystrobin, Pyraclostrobin (2nd), Spirotetramat, Thiacloprid (1st)
- Contribute to ensuring the regional fluctuation of the trials for some candidates.



Trial plan update / as of January 2020

#	CPA name	No. of Ctry	- '17	'18	'19	'20	'21	'22	Total	Remark
II-1	Propiconazole									Deleted
II-2	Trifloxystrobin	4		1	3	6	5	3	18	
II-3	Chlorfluazuron	1			1	1	1		3	
II-4	Fluopicolide	3	29	4	4	4	4		45	
II-5	Pyraclostrobin	4		1	3	6	5	3	18	
II-6	Myclobutanil									Remove
II-7	S-metolachlor	5		1	13	13	12		39	
II-8	Mandipropamid	4	11		6	7	7		31	
II-9	Cyantraniliprole	2			6	6	6		18	For verification

Completed

On going / Plan



Trial Status update

/ as of September

❖ Trials in 2020 Crop

- During these unprecedented times, most of trials were carried out as per planning.

❖ S-metolachlor, Mandipropamid and Cyantraniliprole

- Trials for above CPAs in US, half of trials by NCSU were canceled due to public health reasons.
- Trial for Mandipropamid in Philippines was canceled due to product availability issue.

❖ Sample shipments / residue analysis

- COVID-19 outbreak may affect the sample shipment to JPN, some samples from finished trials have not arrived to JT laboratory.
- JT laboratory has lost ordinary functions of residue analysis since the end of February but it has almost recovered now.



Trial Status update

/ as of September

#	CPA name	No. of Ctry	- '17	'18	'19	'20	'21	'22	Total	Remark	
II-1	Propiconazole									Delisted	
II-2	Trifloxystrobin	4		1	3	6	5	3	18		
II-3	Chlorfluazuron	1			1	1	1		3		
II-4	Fluopicolide	3	29	4	3	1	4	4	45		
II-5	Pyraclostrobin	4		1	3	1	5	5	3	18	
II-6	Myclobutanil									Removed	
II-7	S-metolachlor	5		1	8	5	$13 \Rightarrow 12$ 12	12	39 \Rightarrow 38		
II-8	Mandipropamid	4	10		5	1	$7 \Rightarrow 5$ 5	7	31 \Rightarrow 29		
II-9	Cyantraniliprole	2		1	5	1	$6 \Rightarrow 5$ 5	5	18 \Rightarrow 17	For verification	

Completed

On going / Plan

❖ **Trials for CPAs in 1st generation candidates**

- **Trials for 5 CPAs have been finished.**
 - The data obtained from the trials will be used to discuss future technical GRLs.
- **Trials for 2 CPAs are in progress and will be finished in 2022.**

❖ **Trials for CPAs in 2nd generation candidates**

- **Additional trials were planned for S-metolachlor by Argentine executors.**
- **Indian executor agreed to participate in the future trials for 4 CPAs from 2020-2022.**
- **Above trials will contribute to ensuring the regional fluctuation of the trials.**
- **Trials for 7 CPAs are in progress and all trials for them will be finished in 2022.**

❖ **Influence of COVID-19**

- **During these unprecedented times, most of trials were carried out as per planning.**
 - Some trials were canceled in US due to public health reasons.
- **Sample shipment to JPN may be affected by outbreak of COVID-19.**
- **JT laboratory has lost ordinary functions of residue analysis since the end of February but it has almost recovered now.**



Thank you for your attention

naoki.watanabe@jt.com